Table 5.
Study group | Multiple comparisons | P-value | |
---|---|---|---|
IL-6 [pg/ml]: | |||
Adalimumab | 0 vs. 12 | 0.0006 | |
0 vs. 24 | 0.0208 | ||
0 vs. 36 | 0.0018 | ||
Etanercept | 0 vs. 3 | 0.0046 | |
Infliximab | 0 vs. 36 | 0.0132 | |
Ustekinumab | 3 vs. 12 | 0.0137 | |
IL-22 [pg/ml]: | |||
Adalimumab | 0 vs. 12 | 0.0247 | |
0 vs. 24 | 0.0004 | ||
0 vs. 36 | 0.0040 | ||
Infliximab | 0 vs. 36 | 0.0235 |